The Italian guidelines for early intervention in schizophrenia: Development and conclusions

Early Intervention in Psychiatry

Volumn 2, Issue 4, 2008, Pages 291-302

  De Masi, Salvatore ^a   Sampaolo, Letizia ^b   Mele, Alfonso ^b   Morciano, Cristina ^b   Cappello, Salvatore ^c   Meneghelli, Anna ^d   de Girolamo, Giovanni ^e  

^a ASL6 Livorno ^*  (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c ASL Latina   (Italy)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e Health Care Research Agency   (Italy)

Author keywords

Early diagnosis; Guidelines; Prognosis; Schizophrenia; Treatment outcome

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE;

ARTICLE; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; DISEASE COURSE; DRUG EFFICACY; EARLY DIAGNOSIS; EARLY INTERVENTION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; ITALY; LOW DRUG DOSE; MENTAL HEALTH SERVICE; METABOLIC DISORDER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; RISK FACTOR; SOCIAL ADAPTATION; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; EARLY DIAGNOSIS; HUMANS; ITALY; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 65249094171     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/j.1751-7893.2008.00091.x     Document Type: Article

References (138)

1. Murray CJ, Lopez AD, Jamison DT. The global burden of disease in 1990: summary results, sensitivity analysis and future directions. Bull World Health Organ 1994; 72 (3): 495-509.
2. Programma Nazionale per le Linee Guida - PNLG, Istituto Superiore di Sanità, Agenzia per i Servizi Sanitari Regionali, Manuale metodologico. Come produrre, diffondere e aggiornare raccomandazioni per la pratica clinica. Milano: Zadig, 2002.
3. Scottish Intercollegiate Guidelines Network's. SIGN Publication No 50. A guideline developers' handbook. Harbor RT. (ed.). SIGH Executive. Elliot House, 8-10 Hillside Crescent, Edimburgh EH75EA. March 2004 edition.
4. Larsen TK, Friis S, Haahr U et al. Early detection and intervention in first-episode schizophrenia: A critical review. Acta Psychiatr Scand 2001; 103 (5): 323-34. Review.
5. Yung AR, Yuen HP, McGorry PD et al. Mapping the onset of psychosis: The Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry 2005; 39 (11-12): 964-71.
6. Miller TJ, McGlashan TH, Rosen JL et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: Preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry 2002; 159 (5): 863-5.
7. Miller TJ, McGlashan TH, Rosen JL et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: Predictive validity, interrater reliability, and training to reliability. Schizophr Bull 2003; 29 (4): 703-15.
8. Morrison AP, Bentall RP, French P et al. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high-risk individuals. Study design and interim analysis of transition rate and psychological risk factors. Br J Psychiatry Suppl 2002; 43: 78-84.
9. Lencz T, Smith CW, Auther AM, Correll CU, Cornblatt BA. The assessment of 'prodromal schizophrenia': Unresolved issues and future directions. Schizophr Bull 2003; 29 (4): 717-28.
10. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: Psychopathology and clinical features. Schizophr Res 2004; 67 (2-3): 131-42.
11. Mason O, Startup M, Halpin S, Schall U, Conrad A, Carr V. Risk factors for transition to first-episode psychosis among individuals with 'at-risk mental states'. Schizophr Res 2004; 71 (2-3): 227-37.
12. Klosterkotter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001; 58 (2): 158-64.
13. Hambrecht M, Lammertink M, Klosterkotter J, Matuschek E, Pukrop R. Subjective and objective neuropsychological abnormalities in a psychosis prodrome clinic'. Br J Psychiatry Suppl 2002; 43: 30-7.
14. Chapman LJ, Chapman JP, Kwapil TR, Eckblad M, Zinser MC. Putatively psychosis-prone subjects 10 years later. J Abnorm Psychol 1994; 103 (2): 171-83.
15. Kwapil TR. Social anhedonia as a predictor of the development of schizophrenia-spectrum disorders. J Abnorm Psychol 1998; 107 (4): 558-65.
16. Gooding DC, Tallent KA, Matts CW. Clinical status of at-risk individuals 5 years later: Further validation of the psychometric high-risk strategy. J Abnorm Psychol 2005; 114 (1): 170-5.
17. Wood SJ, Pantelis C, Proffitt T et al. Spatial working memory ability is a marker of risk-for-psychosis. Psychol Med 2003; 33 (7): 1239-47.
18. Brewer WJ, Francey SM, Wood SJ et al. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am J Psychiatry 2005; 162 (1): 71-8.
19. Brewer WJ, Wood SJ, McGorry PD et al. Impairment of olfactory identification ability in individuals at ultra-high risk for psychosis who later develop schizophrenia. Am J Psychiatry 2003; 160 (10): 1790-4.
20. Johnstone EC, Ebmeier KP, Miller P, Owens DG, Lawrie SM. Predicting schizophrenia: Findings from the Edinburgh High-Risk Study. Br J Psychiatry 2005; 186: 18-25.
21. Phillips LJ, Velakoulis D, Pantelis C et al. Non-reduction in hippocampal volume is associated with higher risk of psychosis. Schizophr Res 2002; 58 (2-3): 145-58.
22. Garner B, Pariante CM, Wood SJ et al. Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis. Biol Psychiatry 2005; 58 (5): 417-23.
23. Pantelis C, Velakoulis D, McGorry PD et al. Neuroanatomical abnormalities before and after onset of psychosis: A cross-sectional and longitudinal MRI comparison. Lancet 2003; 361 (9354): 281-8.
24. Job DE, Whalley HC, Johnstone EC, Lawrie SM. Grey matter changes over time in high risk subjects developing schizophrenia. Neuroimage 2005; 25 (4): 1023-30.
25. Woods SW, Breier A, Zipursky RB et al. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. (Published erratum appears in Biol Psychiatry 2003; 54 (4): P. 497) Biol Psychiatry 2003; 54 (4): 453-64.
26. McGorry PD, Yung AR, Phillips LJ et al. Randomized controlled trial of intervention designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59 (10): 921-8.
27. McGlashan TH, Zipursky RB, Perkins D et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163 (5): 790-9.
28. Morrison AP, Bentall RP, French P et al. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high-risk individuals. Study design and interim analysis of transition rate and psychological risk factors. Br J Psychiatry Suppl 2002; 43: 78-84.
29. Morrison AP, French P, Walford L et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: Randomised controlled trial. Br J Psychiatry 2004; 185: 291-7.
30. Morrison AS. Screening in Chronic Disease, 2nd edn. Oxford: Oxford University Press, 1992.
31. Johannessen JO, McGlashan TH, Larsen TK et al. Early detection strategies for untreated first-episode psychosis. Schizophr Res 2001; 51 (1): 39-46.
32. Johannessen JO, Larsen TK, Joa I et al. Pathways to care for first-episode psychosis in an early detection healthcare sector: Part of the Scandinavian TIPS study. Br J Psychiatry Suppl 2005; 48: 24-8.
33. Malla A, Norman R, Scholten D, Manchanda R, McLean T. A community intervention for early identification of first-episode psychosis: Impact on duration of untreated psychosis (DUP) and patient characteristics. Soc Psychiatry Psychiatr Epidemiol 2005; 40 (5): 337-44.
34. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: A critical review and meta-analysis. Am J Psychiatry 2005; 162 (10): 1785-804.
35. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: A systematic review. Arch Gen Psychiatry 2005; 62 (9): 975-83.
36. Norman RM, Lewis SW, Marshall M. Duration of untreated psychosis and its relationship to clinical outcome. Br J Psychiatry Suppl 2005; 48: 19-23.
37. Rund BR, Melle I, Friis S et al. Neurocognitive dysfunction in first-episode psychosis: Correlates with symptoms, premorbid adjustment, and duration of untreated psychosis. Am J Psychiatry 2004; 161 (3): 466-72.
38. Ucok A, Polat A, Genc A, Cakir S, Turan N. Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia. J Psychiatr Res 2004; 38 (2): 163-8.
39. Addington J, Van Mastrigt S, Addington D. Duration of untreated psychosis: Impact on 2-year outcome. Psychol Med 2004; 34 (2): 277-84.
40. Oosthuizen P, Emsley RA, Keyter N, Niehaus DJ, Koen L. Duration of untreated psychosis and outcome in first-episode psychosis. Perspective from a developing country. Acta Psychiatr Scand 2005; 111 (3): 214-9.
41. Pek E, Mythily S, Chong SA. Clinical and social correlates of duration of untreated psychosis in first-episode psychosis patients. Ann Acad Med Singapore 2006; 35 (1): 24-6.
42. Gunduz-Bruce H, McMeniman M, Robinson DG etal. Duration of untreated psychosis and time to treatment response for delusions and hallucinations. Am J Psychiatry 2005; 162 (10): 1966-9.
43. Harris MG, Henry LP, Harrigan SM et al. The relationship between duration of untreated psychosis and outcome: An eight-year prospective study. Schizophr Res 2005; 79 (1): 85-93.
44. Melle I, Haahr U, Friis S et al. Reducing the duration of untreated first-episode psychosis-effects on baseline social functioning and quality of life. Acta Psychiatr Scand 2005; 112 (6): 469-73.
45. Rufino AC, Uchida RR, Vilela JA, Marques JM, Zuardi AW, Del-Ben CM. Stability of the diagnosis of first-episode psychosis made in an emergency setting. Gen Hosp Psychiatry 2005; 27 (3): 189-93.
46. Whitty P, Clarke M, McTigue O et al. Diagnostic stability four years after a first-episode of psychosis. Psychiatr Serv 2005; 56 (9): 1084-8.
47. Schimmelmann BG, Conus P, Edwards J, McGorry PD, Lambert M. Diagnostic stability 18 months after treatment initiation for first-episode psychosis. J Clin Psychiatry 2005; 66 (10): 1239-46.
48. Gelber EI, Kohler CG, Bilker WB et al. Symptom and demographic profiles in first-episode schizophrenia. Schizophr Res 2004; 67 (2-3): 185-94.
49. Vita A, De Peri L, Silenzi C, Dieci M. Brain morphology in first-episode schizophrenia: A meta-analysis of quantitative magnetic resonance imaging studies. Schizophr Res 2006; 82 (1): 75-88. Epub 2005 Dec 27.
50. Molina V, Sanz J, Reig S et al. Hypofrontality in men with first-episode psychosis. Br J Psychiatry 2005; 186: 203-8.
51. Wood SJ, Velakoulis D, Smith DJ et al. A longitudinal study of hippocampal volume in first-episode psychosis and chronic schizophrenia. Schizophr Res 2001; 52 (1-2): 37-46.
52. Whitworth AB, Kemmler G, Honeder M etal. Longitudinal volumetric MRI study in first- and multiple-episode male schizophrenia patients. Psychiatry Res 2005; 140 (3): 225-37. Epub 2005 Nov 4.
53. Prasad KM, Patel AR, Muddasani S, Sweeney J, Keshavan MS. The entorhinal cortex in first-episode psychotic disorders: A structural magnetic resonance imaging study. Am J Psychiatry 2004; 161 (9): 1612-9.
54. Velakoulis D, Wood SJ, Wong MT et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: A magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry 2006; 63 (2): 139-49.
55. Whitford TJ, Farrow TF, Gomes L, Brennan J, Harris AW, Williams LM. Grey matter deficits and symptom profile in first-episode schizophrenia. Psychiatry Res 2005; 139 (3): 229-38.
56. Narr KL, Bilder RM, Toga AW et al. Mapping cortical thickness and gray matter concentration in first-episode schizophrenia. Cereb Cortex 2005; 15 (6): 708-19. Epub 2004 Sep 15.
57. Narr KL, Toga AW, Szeszko P et al. Cortical thinning in cingulate and occipital cortices in first-episode schizophrenia. Biol Psychiatry 2005; 58 (1): 32-40.
58. Szeszko PR, Goldberg E, Gunduz-Bruce H et al. Smaller anterior hippocampal formation volume in antipsychotic-naive patients with first-episode schizophrenia. Am J Psychiatry 2003; 160 (12): 2190-7.
59. Prasad KM, Patel AR, Muddasani S, Sweeney J, Keshavan MS. The entorhinal cortex in first-episode psychotic disorders: A structural magnetic resonance imaging study. Am J Psychiatry 2004; 161 (9): 1612-9.
60. Narr KL, Thompson PM, Szeszko P et al. Regional specificity of hippocampal volume reductions in first-episode schizophrenia. Neuroimage 2004; 21 (4): 1563-75.
61. McCarley RW, Salisbury DF, Hirayasu Y et al. Association between smaller left posterior superior temporal gyrus volume on magnetic resonance imaging and smaller left temporal P300 amplitude in first-episode schizophrenia. Arch Gen Psychiatry 2002; 59 (4): 321-31.
62. Wiegand LC, Warfield SK, Levitt JJ et al. An in vivo MRI study of prefrontal cortical complexity in first-episode psychosis. Am J Psychiatry 2005; 162 (1): 65-70.
63. Lieberman J, Chakos M, Wu H et al. Longitudinal study of brain morphology in first-episode schizophrenia. Biol Psychiatry 2001; 49 (6): 487-99.
64. Fannon D, Chitnis X, Doku V et al. Features of structural brain abnormality detected in first-episode psychosis. Am J Psychiatry 2000; 157 (11): 1829-34.
65. MacDonald AW 3rd, Carter CS, Kerns JG et al. Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in never-medicated patients with first-episode psychosis. Am J Psychiatry 2005; 162 (3): 475-84.
66. Lee CU, Shenton ME, Salisbury DF et al. Fusiform gyrus volume reduction in first-episode schizophrenia: A magnetic resonance imaging study. Arch Gen Psychiatry 2002; 59 (9): 775-81.
67. Kasai K, Shenton ME, Salisbury DF et al. Differences and similarities in insular and temporal pole MRI gray matter volume abnormalities in first-episode schizophrenia and affective psychosis. Arch Gen Psychiatry 2003; 60 (11): 1069-77.
68. Prasad KM, Rohm BR, Keshavan MS. Parahippocampal gyrus in first-episode psychotic disorders: A structural magnetic resonance imaging study. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28 (4): 651-8.
69. Hirayasu Y, Tanaka S, Shenton ME et al. Prefrontal gray matter volume reduction in first-episode schizophrenia. Cereb Cortex 2001; 11 (4): 374-81.
70. Job DE, Whalley HC, McConnell S, Glabus M, Johnstone EC, Lawrie SM. Structural gray matter differences between first-episode schizophrenics and normal controls using voxel-based morphometry. Neuroimage 2002; 17 (2): 880-9.
71. Hirayasu Y, McCarley RW, Salisbury DF et al. Planum temporale and Heschl gyrus volume reduction in schizophrenia: A magnetic resonance imaging study of first-episode patients. Arch Gen Psychiatry 2000; 57 (7): 692-9.
72. Harris JM, Yates S, Miller P, Best JJ, Johnstone EC, Lawrie SM. Gyrification in first-episode schizophrenia: A morphometric study. Biol Psychiatry 2004; 55 (2): 141-7.
73. Farrow TF, Whitford TJ, Williams LM, Gomes L, Harris AW. Diagnosis-related regional gray matter loss over two years in first-episode schizophrenia and bipolar disorder. Biol Psychiatry 2005 (Nov 1); 58 (9): 713-23. Epub 2005 Jul 5.
74. Narr KL, Bilder RM, Kim S et al. Abnormal gyral complexity in first-episode schizophrenia. Biol Psychiatry 2004; 55 (8): 859-67.
75. Bagary MS, Symms MR, Barker GJ, Mutsatsa SH, Joyce EM, Ron MA. Gray and white matter brain abnormalities in first-episode schizophrenia inferred from magnetization transfer imaging. Arch Gen Psychiatry 2003; 60 (8): 779-88.
76. Bottmer C, Bachmann S, Pantel J et al. Reduced cerebellar volume and neurological soft signs in first-episode schizophrenia. Psychiatry Res 2005; 140 (3): 239-50. Epub 2005 Nov 8.
77. Molina V, Sanz J, Sarramea F, Luque R, Benito C, Palomo T. Dorsolateral prefrontal and superior temporal volume deficits in first-episode psychoses that evolve into schizophrenia. Eur Arch Psychiatry Clin Neurosci 2006; 256 (2): 106-11. Epub 2005 Sep 14.
78. Malla AK, Mittal C, Lee M, Scholten DJ, Assis L, Norman RM. Computed tomography of the brain morphology of patients with first-episode schizophrenic psychosis. J Psychiatry Neurosci 2002; 27 (5): 350-8.
79. Symond MP, Harris AW, Gordon E, Williams LM. 'Gamma synchrony' in first-episode schizophrenia: A disorder of temporal connectivity? (Published erratum appears in Am J Psychiatry 2005; 162 (5): 1042. Symond, Matthew B [corrected to Symond, Matthew P]) Am J Psychiatry 2005; 162 (3): 459-65.
80. Taiminen T, Jaaskelainen S, Ilonen T et al. Habituation of the blink reflex in first-episode schizophrenia, psychotic depression and non-psychotic depression. Schizophr Res 2000; 44 (1): 69-79.
81. Townsend LA, Norman RM. Course of cognitive functioning in first-episode schizophrenia spectrum disorders. Expert Rev Neurother 2004; 4 (1): 61-8.
82. Fitzgerald D, Lucas S, Redoblado MA et al. Cognitive functioning in young people with first-episode psychosis: Relationship to diagnosis and clinical characteristics. Aust N Z J Psychiatry 2004; 38 (7): 501-10.
83. Rodriguez-Sanchez JM, Crespo-Facorro B, Perez-Iglesias R et al. Prefrontal cognitive functions in stabilized first-episode patients with schizophrenia spectrum disorders: A dissociation between dorsolateral and orbitofrontal functioning. Schizophr Res 2005; 77 (2-3): 279-88.
84. Riley EM, McGovern D, Mockler D et al. Neuropsychological functioning in first-episode psychosis-evidence of specific deficits. Schizophr Res 2000; 43 (1): 47-55.
85. Nuyen J, Sitskoorn MM, Cahn W, Kahn RS. Verbal memory in first-episode schizophrenia: Heterogeneity in performance? J Int Neuropsychol Soc 2005; 11 (2): 152-62.
86. Edwards J, Pattison PE, Jackson HJ, Wales RJ. Facial affect and affective prosody recognition in first-episode schizophrenia. Schizophr Res 2001; 48 (2-3): 235-53.
87. Dazzan P, Morgan KD, Orr KG et al. The structural brain correlates of neurological soft signs in AESOP first-episode psychoses study. Brain 2004; 127 (Pt 1): 143-53. Epub 2003 Oct 21.
88. Boks MP, Liddle PF, Burgerhof JG, Knegtering R, van den Bosch RJ. Neurological soft signs discriminating mood disorders from first-episode schizophrenia. Acta Psychiatr Scand 2004; 110 (1): 29-35.
89. Bachmann S, Bottmer C, Schroder J. Neurological soft signs in first-episode schizophrenia: A follow-up study. Am J Psychiatry 2005; 162 (12): 2337-43.
90. Moreno D, Burdalo M, Reig S et al. Structural neuroimaging in adolescents with a first psychotic episode. J Am Acad Child Adolesc Psychiatry 2005; 44 (11): 1151-7.
91. Lubman DI, Velakoulis D, McGorry PD et al. Incidental radiological findings on brain magnetic resonance imaging in first-episode psychosis and chronic schizophrenia. Acta Psychiatr Scand 2002; 106 (5): 331-6.
92. Wood SJ, Berger G, Velakoulis D et al. Proton magnetic resonance spectroscopy in first-episode psychosis and ultra high-risk individuals. Schizophr Bull 2003; 29 (4): 831-43.
93. Preuss UW, Zetzsche T, Jager M et al. Thalamic volume in first-episode and chronic schizophrenic subjects: A volumetric MRI study. Schizophr Res 2005; 73 (1): 91-101.
94. Dazzan P, Murray RM. Neurological soft signs in first-episode psychosis: a systematic review. Br J Psychiatry Suppl 2002; 43: 50-7. Review.
95. Bradford DW, Perkins DO, Lieberman JA. Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. Drugs 2003; 63 (21): 2265-83.
96. Robinson DG, Woerner MG, Delman HM, Kane JM. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull 2005; 31 (3): 705-22. Epub 2005 Jul 8.
97. Lieberman JA, Tollefson G, Tohen M et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003; 160 (8): 1396-404.
98. Schooler N, Rabinowitz J, Davidson M et al. Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial. Am J Psychiatry 2005; 162 (5): 947-53.
99. Perkins DO, Johnson JL, Hamer RM et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res 2006; 83 (1): 53-63. Epub 2006 Mar 9.
100. Zipursky RB, Gu H, Green AI et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005; 187: 537-43.
101. Keefe RS, Seidman LJ, Christensen BK et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004; 161 (6): 985-95.
102. Keefe RS, Seidman LJ, Christensen BK et al. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol Psychiatry 2006; 59 (2): 97-105. Epub 2005 Sep 2.
103. Oosthuizen P, Emsley R, Jadri Turner H, Keyter N. A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. Int J Neuropsychopharmacol 2004; 7 (2): 125-31. Epub 2004 Mar 5.
104. Merlo MC, Hofer H, Gekle W et al. Risperidone, 2mg/day vs. 4mg/day, in first-episode, acutely psychotic patients: Treatment efficacy and effects on fine motor functioning. J Clin Psychiatry 2002; 63 (10): 885-91.
105. Lambert M, Conus P, Schimmelmann BG et al. Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: Results of an open retrospective medical record study. Pharmacopsychiatry 2005; 38 (5): 206-13.
106. Montes JM, Ciudad A, Gascon J, JC G, EFESO Study G. Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: A naturalistic study. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27 (4): 667-74.
107. Bobes J, Gibert J, Ciudad A et al. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27 (3): 473-81.
108. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005; 39 (1-2): 1-30.
109. National Institute for Clinical Excellence. Schizophrenia. Core intervention in the treatment and management of schizophrenia in primary and secondary care. Clinical guideline no. 1, December 2002;
110. Lehman AF, Lieberman JA, Dixon LB et al. American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edniton. Am J Psychiatry 2004; 161 (Suppl. 2): 1-56.
111. Lehman AF, Kreyenbuhl J, Buchanan RW et al. The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003. Schizophr Bull 2004; 30 (2): 193-217.
112. Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry 2005; 50 (13 Suppl 1): 7S-57S.
113. Robinson DG, Woerner MG, Delman HM, Kane JM. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull 2005; 31 (3): 705-22. Epub 2005 Jul 8.
114. Bradford DW, Perkins DO, Lieberman JA. Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. Drugs 2003; 63 (21): 2265-83.
115. Gaebel W, Janner M, Frommann N et al. First vs multiple episode schizophrenia: Two-year outcome of intermittent and maintenance medication strategies. Schizophr Res 2002; 53 (1-2): 145-59.
116. Pilling S, Bebbington P, Kuipers E et al. Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. Psychol Med 2002; 32 (5): 763-82.
117. Petersen L, Nordentoft M, Jeppesen P et al. Improving 1-year outcome in first-episode psychosis: OPUS trial. Br J Psychiatry Suppl 2005; 48: 98-103.
118. Tarrier N, Lewis S, Haddock G et al. Cognitive-behavioural therapy in first-episode and early schizophrenia. 18-month follow-up of a randomised controlled trial. Br J Psychiatry 2004; 184: 231-9.
119. Malla A, Norman R, McLean T, Scholten D, Townsend LA. Canadian programme for early intervention in non-affective psychotic disorders. Aust N Z J Psychiatry 2003; 37 (4): 407-13.
120. Falloon IR. General practice recruitment for people at risk of schizophrenia: The Buckingham experience. Aust N Z J Psychiatry 2000; Nov (Suppl. 34): 131-6. discussion discussion 140-4.
121. McGorry PD, Yung AR, Phillips LJ. The 'close-in' or ultra high-risk model: A safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. Schizophr Bull 2003; 29 (4): 771-90.
122. McGorry PD, Killackey EJ. Early intervention in psychosis: A new evidence based paradigm. Epidemiol Psichiatr Soc 2002; 11 (4): 237-47.
123. Chong SA, Lee C, Bird L, Verma S. A risk reduction approach for schizophrenia: The Early Psychosis Intervention Programme. Ann Acad Med Singapore 2004; 33 (5): 630-5.
124. Broome MR, Woolley JB, Johns LC et al. Outreach and support in south London (OASIS): Implementation of a clinical service for prodromal psychosis and the at risk mental state. Eur Psychiatry 2005; 20 (5-6): 372-8.
125. Miller TJ, McGlashan TH. Early identification and intervention in psychotic illness. Conn Med 2000; 64 (6): 339-41.
126. Heinssen RK, Perkins DO, Appelbaum PS, Fenton WS. Informed consent in early psychosis research: National institute of mental health workshop, November 15, 2000. Schizophr Bull 2001; 27 (4): 571-83.
127. Cornblatt BA. The New York high risk project to the Hillside recognition and prevention (RAP) program. Am J Med Genet 2002; 114 (8): 956-66.
128. Petersen L, Jeppesen P, Thorup A et al. A randomised multicentre trial of integrated versus standard treatment for patients with a first-episode of psychotic illness. (Published erratum appears in BMJ 2005; 331 (7524): 1065) BMJ 2005; 331 (7517): 602. Epub 2005 Sep 2.
129. Edwards J, Harris MG, Bapat S. Developing services for first-episode psychosis and the critical period. Br J Psychiatry Suppl 2005; 48: 91-7.
130. Cullberg J, Levander S, Holmqvist R, Mattsson M, Wieselgren IM. One-year outcome in first-episode psychosis patients in the Swedish Parachute project. Acta Psychiatr Scand 2002; 106 (4): 276-85.
131. de Haan L, van Raaij B, van den Berg R et al. Preferences for treatment during a first psychotic episode. Eur Psychiatry 2001; 16 (2): 83-9.
132. Archie S, Wilson JH, Woodward K, Hobbs H, Osborne S, McNiven J. Psychotic disorders clinic and first-episode psychosis: A program evaluation. Can J Psychiatry 2005; 50 (1): 46-51.
133. O'Toole MS, Ohlsen RI, Taylor TM, Purvis R, Walters J, Pilowsky LS. Treating first-episode psychosis-the service users' perspective: A focus group evaluation. J Psychiatr Ment Health Nurs 2004; 11 (3): 319-26.
134. Fuchs J, Steinert T. Patients with a first-episode of schizophrenia spectrum psychosis and their pathways to psychiatric hospital care in South Germany. Soc Psychiatry Psychiatr Epidemiol 2004; 39 (5): 375-80.
135. Cocchi A, Meneghelli A. L'intervento precoce tra pratica e ricerca. Manuale per il trattamento delle psicosi all'esordio. Torino: Centro Scientifico Editore, 2004.
136. Norman RM, Malla AK, Verdi MB, Hassall LD, Fazekas C. Understanding delay in treatment for first-episode psychosis. Psychol Med 2004; 34 (2): 255-66.
137. Malla AK, Norman RM, Manchanda R et al. Status of patients with first-episode psychosis after one year of phase-specific community-oriented treatment. Psychiatr Serv 2002; 53 (4): 458-63.
138. Filakovic P, Degmecic D, Koic E, Benic D. Ethics of the early intervention in the treatment of schizophrenia. Psychiatr Danub 2007; 19 (3): 209-15.